Schonfeld Strategic Advisors’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-439,812
Closed -$31.7M 2603
2025
Q4
$31.7M Buy
+439,812
New +$28.4M 0.14% 112
2024
Q3
Sell
-5,573
Closed -$228K 2362
2024
Q2
$228K Buy
+5,573
New +$160K ﹤0.01% 1775
2024
Q1
Sell
-130,117
Closed -$1.18M 2347
2023
Q4
$1.18M Buy
130,117
+2,817
+2% +$18.8K 0.01% 975
2023
Q3
$812K Sell
127,300
-7,699
-6% -$66.3K 0.01% 1079
2023
Q2
$1.5M Buy
+134,999
New +$1.69M 0.01% 859
2023
Q1
Sell
-10,700
Closed -$237K 2565
2022
Q4
$237K Buy
+10,700
New +$160K ﹤0.01% 1909
2022
Q1
Sell
-19,531
Closed -$464K 2878
2021
Q4
$464K Buy
+19,531
New +$466K ﹤0.01% 1300
2021
Q1
Sell
-49,110
Closed -$1.25M 2073
2020
Q4
$1.25M Buy
+49,110
New +$1.43M 0.02% 732

Other funds holding RNAM

Schonfeld Strategic Advisors's RNAM Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 439,812 shares — an estimated $31.7M sold.

Schonfeld Strategic Advisors first reported a position in RNAM in Q4 2020 and held it in 8 quarters. The position peaked at $31.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 439,812 Avidity Biosciences shares in Q1 2026, an estimated $31.7M.
  • Schonfeld Strategic Advisors first reported a position in Avidity Biosciences in Q4 2020 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's Avidity Biosciences position peaked at $31.7M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.